KalVista制药 KALV 深 沪
等待开盘 02-05 09:30:00 美东时间
14.98
-1.150
-7.13%
华盛通- 最 高16.53
- 今 开16.21
- 成交量 90.36万股
- 最 低 14.715
- 昨 收 16.13
- 总市值 7.57亿
- 52周最高 19.00
- 市盈率 静 --
- 换手率 1.79%
- 52周最低 9.235
- 委 比 70.55%
- 总股本 5054.63万
- 历史最高 45.00
- 量 比 1.39
- 振 幅 11.25%
- 历史最低 4.12
- 每 手 1
- 风险率 1.88%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多KalVista Pharmaceuticals Grants Stock Options to New Employees
KalVista Pharmaceuticals Grants Stock Options to New Employees KalVista Pharmaceuticals Inc. has granted inducement stock options to six newly-hired employees, allowing them to purchase a total of 96,750 shares of KalVista common stock. The options have an exercise price equal to the closing price o
02-03 20:00
美股大行评级 | 瑞穗上调英伟达、谷歌、美光科技、SanDisk多家科技股目标价；中金首予诺和诺德"跑赢大市"评级，目标价73.5美元
今日重点评级关注：Needham：维持Cartesian Therapeutics"买入"评级，目标价从40美元升至42美元；Piper Sandler：维持Acrivon Therapeutics"超配"评级，目标价从6美元升至8美元
01-12 14:09
KalVista Details Early Sales, Prescriber Uptake For Newly Approved Rare Swelling Drug
KalVista reports early EKTERLY sales momentum, rising prescriber adoption and global regulatory approvals following the drug's 2025 launch.
01-09 22:56
KalVista reports $49M in 2025 Ekterly revenue, shares rise
KalVista Pharmaceuticals (KALV) reported approximately $35 million in global net product revenue from Ekterly (sebetralstat) in the fourth quarter and about $49 million for full-year 2025, sending sha...
01-09 20:19
12 Health Care Stocks Moving In Friday's Pre-Market Session
Gainers China SXT Pharmaceuticals (NASDAQ:SXTC) stock increased by 19.2% to $1...
01-09 20:05
Greenbrier, General Motors And 3 Stocks To Watch Heading Into Friday
With U.S. stock futures trading slightly lower this morning on Friday, some of ...
01-09 19:06
Why Tilray Brands Shares Are Trading Higher By Over 7%; Here Are 20 Stocks Moving Premarket
Shares of Tilray Brands Inc (NASDAQ:TLRY) rose sharply in pre-market trading af...
01-09 17:46
美股大行评级 | 拼多多、小鹏获Freedom上调目标价；多家大行首予Wealthfront"超配"评级，目标价最高23美元
今日重点评级关注：HC Wainwright & Co.：维持MetaVia Inc."买入"评级，目标价从12美元升至40美元；Canaccord Genuity：维持GH Research"买入"评级，目标价从35美元升至39美元
01-07 17:25
Needham Maintains Buy on KalVista Pharmaceuticals, Raises Price Target to $32
Needham analyst Serge Belanger maintains KalVista Pharmaceuticals (NASDAQ:KALV) with a Buy and raises the price target from $28 to $32.
01-06 18:55
2026美股生物科技板块怎么投资？杰富瑞：关注6大首选、7大潜力和5大并购目标
杰富瑞近日发布了关于 2026 年美股生物科技行业的展望报告，聚焦行业首选投资标的、被低估的潜力企业和潜在并购机会。
2025-12-25 15:40
